A single, engineered protein therapeutic agent neutralizes exotoxins from both Staphylococcus aureus and Streptococcus pyogenes

Clinical and Vaccine Immunology

Volumn 17, Issue 11, 2010, Pages 1781-1789

  Wang, Ningyan ^a   Mattis, Daiva M ^a   Sundberg, Eric J ^b   Schlievert, Patrick M ^c   Kranz, David M ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^b BOSTON BIOMEDICAL RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EXOTOXIN; MUTANT PROTEIN; STAPHYLOCOCCUS ENTEROTOXIN B; STAPHYLOCOCCUS ENTEROTOXIN C; STREPTOCOCCAL PYROGENIC EXOTOXIN A; T LYMPHOCYTE RECEPTOR BETA CHAIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; CROSS REACTION; EXPERIMENTAL RABBIT; MUTATIONAL ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN ENGINEERING; PROTEIN STRUCTURE; PROTEIN VARIANT; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PYOGENES;

ANIMALS; ANTITOXINS; BACTERIAL PROTEINS; CROSS REACTIONS; ENTEROTOXINS; EXOTOXINS; MEMBRANE PROTEINS; PROTEIN BINDING; RABBITS; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; RECOMBINANT PROTEINS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PYOGENES; SUPERANTIGENS; SURVIVAL ANALYSIS; VIRULENCE FACTORS;

EID: 78449251755     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00277-10     Document Type: Article

References (53)

1. Abe, J., B. L. Kotzin, K. Jujo, M. E. Melish, M. P. Glode, T. Kohsaka, and D. Y. Leung. 1992. Selective expansion of T cells expressing T-cell receptor variable regions V beta 2 and V beta 8 in Kawasaki disease. Proc. Natl. Acad. Sci. U. S. A. 89:4066-4070.
2. Andersen, P. S., C. Geisler, S. Buus, R. A. Mariuzza, and K. Karjalainen. 2001. Role of TCR-ligand affinity in T cell activation by bacterial superantigens. J. Biol. Chem. 276:33452-33457.
3. Bachert, C., P. Gevaert, N. Zhang, T. van Zele, and C. Perez-Novo. 2007. Role of staphylococcal superantigens in airway disease. Chem. Immunol. Allergy 93:214-236.
4. Bergdoll, M. S., and P. M. Schlievert. 1984. Toxic-shock syndrome toxin. Lancet ii:691.
5. Bohach, G. A., C. J. Hovde, J. P. Handley, and P. M. Schlievert. 1988. Cross-neutralization of staphylococcal and streptococcal pyrogenic toxins by monoclonal and polyclonal antibodies. Infect. Immun. 56:400-404.
6. Brower, V. 1997. Enbrel's phase III reinforces prospects in RA. Nat. Biotechnol. 15:1240.
7. Bubeck Wardenburg, J., R. J. Patel, and O. Schneewind. 2007. Surface proteins and exotoxins are required for the pathogenesis of Staphylococcus aureus pneumonia. Infect. Immun. 75:1040-1044.
8. Bueno, C., C. D. Lemke, G. Criado, M. L. Baroja, S. S. Ferguson, A. K. Rahman, C. D. Tsoukas, J. K. McCormick, and J. Madrenas. 2006. Bacterial superantigens bypass Lck-dependent T cell receptor signaling by activating a Galpha11-dependent, PLC-beta-mediated pathway. Immunity 25:67-78. (Pubitemid 44066827)
9. Buonpane, R. A., H. R. Churchill, B. Moza, E. J. Sundberg, M. L. Peterson, P. M. Schlievert, and D. M. Kranz. 2007. Neutralization of staphylococcal enterotoxin B by soluble, high-affinity receptor antagonists. Nat. Med. 13: 725-729.
10. Buonpane, R. A., B. Moza, E. J. Sundberg, and D. M. Kranz. 2005. Characterization of T cell receptors engineered for high affinity against toxic shock syndrome toxin-1. J. Mol. Biol. 353:308-321.
11. Churchill, H. R., P. S. Andersen, E. A. Parke, R. A. Mariuzza, and D. M. Kranz. 2000. Mapping the energy of superantigen Staphylococcus enterotoxin C3 recognition of an alpha/beta T cell receptor using alanine scanning mutagenesis. J. Exp. Med. 191:835-846.
12. Cleary, P. P., E. L. Kaplan, J. P. Handley, A. Wlazlo, M. H. Kim, A. R. Hauser, and P. M. Schlievert. 1992. Clonal basis for resurgence of serious Streptococcus pyogenes disease in the 1980s. Lancet 339:518-521.
13. Cone, L. A., R. A. Stone, P. M. Schlievert, R. A. Sneider, A. M. Rubin, K. Jesser, and S. W. Renker. 2006. An early favorable outcome of streptococcal toxic shock syndrome may require a combination of antimicrobial and intravenous gamma globulin therapy together with activated protein C. Scand. J. Infect. Dis. 38:960-963.
14. Cone, L. A., D. R. Woodard, P. M. Schlievert, and G. S. Tomory. 1987. Clinical and bacteriologic observations of a toxic shock-like syndrome due to Streptococcus pyogenes. N. Engl. J. Med. 317:146-149.
15. Davis, J. P., P. J. Chesney, P. J. Wand, and M. LaVenture. 1980. Toxic-shock syndrome: epidemiologic features, recurrence, risk factors, and prevention. N. Engl. J. Med. 303:1429-1435.
16. Demers, B., A. E. Simor, H. Vellend, P. M. Schlievert, S. Byrne, F. Jamieson, S. Walmsley, and D. E. Low. 1993. Severe invasive group A streptococcal infections in Ontario, Canada: 1987-1991. Clin. Infect. Dis. 16:792-802.
17. Dinges, M. M., and P. M. Schlievert. 2001. Comparative analysis of lipopolysaccharide- induced tumor necrosis factor alpha activity in serum and lethality in mice and rabbits pretreated with the staphylococcal superantigen toxic shock syndrome toxin 1. Infect. Immun. 69:7169-7172.
18. Fernandez, M. M., S. Bhattacharya, M. C. De Marzi, P. H. Brown, M. Kerzic, P. Schuck, R. A. Mariuzza, and E. L. Malchiodi. 2007. Superantigen natural affinity maturation revealed by the crystal structure of staphylococcal enterotoxin G and its binding to T-cell receptor Vbeta8.2. Proteins 68:389-402.
19. Fields, B. A., E. L. Malchiodi, H. Li, X. Ysern, C. V. Stauffacher, P. M. Schlievert, K. Karjalainen, and R. A. Mariuzza. 1996. Crystal structure of a T-cell receptor b-chain complexed with a superantigen. Nature 384:188-192.
20. Holler, P. D., and D. M. Kranz. 2003. Quantitative analysis of the contribution of TCR/pepMHC affinity and CD8 to T cell activation. Immunity 18: 255-264.
21. John, C. C., M. Niermann, B. Sharon, M. L. Peterson, D. M. Kranz, and P. M. Schlievert. 2009. Staphylococcal toxic shock syndrome erythroderma is associated with superantigenicity and hypersensitivity. Clin. Infect. Dis. 49: 1893-1896.
22. Kansal, R. G., V. Datta, R. K. Aziz, N. F. Abdeltawab, S. Rowe, and M. Kotb. 2010. Dissection of the molecular basis for hypervirulence of an in vivo-selected phenotype of the widely disseminated M1T1 strain of group A Streptococcus bacteria. J. Infect. Dis. 201:855-865.
23. Kaul, R., A. McGeer, A. Norrby-Teglund, M. Kotb, B. Schwartz, K. O'Rourke, J. Talbot, and D. E. Low. 1999. Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome - a comparative observational study. The Canadian Streptococcal Study Group. Clin. Infect. Dis. 28:800-807.
24. Kieke, M. C., E. Sundberg, E. V. Shusta, R. A. Mariuzza, K. D. Wittrup, and D. M. Kranz. 2001. High affinity T cell receptors from yeast display libraries block T cell activation by superantigens. J. Mol. Biol. 307:1305-1315.
25. Kline, J. B., and C. M. Collins. 1996. Analysis of the superantigenic activity of mutant and allelic forms of streptococcal pyrogenic exotoxin A. Infect. Immun. 64:861-869.
26. Kotb, M., A. Norrby-Teglund, A. McGeer, H. El-Sherbini, M. T. Dorak, A. Khurshid, K. Green, J. Peeples, J. Wade, G. Thomson, B. Schwartz, and D. E. Low. 2002. An immunogenetic and molecular basis for differences in outcomes of invasive group A streptococcal infections. Nat. Med. 8:1398-1404.
27. Lappin, E., and A. J. Ferguson. 2009. Gram-positive toxic shock syndromes. Lancet Infect. Dis. 9:281-290.
28. Leung, D. Y., R. C. Giorno, L. V. Kazemi, P. A. Flynn, and J. B. Busse. 1995. Evidence for superantigen involvement in cardiovascular injury due to Kawasaki syndrome. J. Immunol. 155:5018-5021.
29. Li, H., A. Llera, E. L. Malchiodi, and R. A. Mariuzza. 1999. The structural basis of T cell activation by superantigens. Annu. Rev. Immunol. 17:435-466.
30. Li, H., A. Llera, D. Tsuchiya, L. Leder, X. Ysern, P. M. Schlievert, K. Karjalainen, and R. A. Mariuzza. 1998. Three-dimensional structure of the complex between a T cell receptor beta chain and the superantigen staphylococcal enterotoxin B. Immunity 9:807-816.
31. Malchiodi, E. L., E. Eisenstein, B. A. Fields, D. H. Ohlendorf, P. M. Schlievert, K. Karjalainen, and R. A. Mariuzza. 1995. Superantigen binding to a T cell receptor b chain of known three-dimensional structure. J. Exp. Med. 182:1833-1845.
32. Marrack, P., and J. Kappler. 1990. The staphylococcal enterotoxins and their relatives. Science 248:705-711.
33. McCormick, J. K., T. J. Tripp, S. B. Olmsted, Y. V. Matsuka, P. J. Gahr, D. H. Ohlendorf, and P. M. Schlievert. 2000. Development of streptococcal pyrogenic exotoxin C vaccine toxoids that are protective in the rabbit model of toxic shock syndrome. J. Immunol. 165:2306-2312.
34. McCormick, J. K., J. M. Yarwood, and P. M. Schlievert. 2001. Toxic shock syndrome and bacterial superantigens: an update. Annu. Rev. Microbiol. 55:77-104.
35. Pragman, A. A., J. M. Yarwood, T. J. Tripp, and P. M. Schlievert. 2004. Characterization of virulence factor regulation by SrrAB, a two-component system in Staphylococcus aureus. J. Bacteriol. 186:2430-2438.
36. Proft, T., S. L. Moffatt, C. J. Berkahn, and J. D. Fraser. 1999. Identification and characterization of novel superantigens from Streptococcus pyogenes. J. Exp. Med. 189:89-102.
37. Proft, T., B. Schrage, and J. D. Fraser. 2007. The cytokine response to streptococcal superantigens varies between individual toxins and between individuals: implications for the pathogenesis of group A streptococcal diseases. J. Interferon Cytokine Res. 27:553-557.
38. Roggiani, M., J. A. Stoehr, S. B. Olmsted, Y. V. Matsuka, S. Pillai, D. H. Ohlendorf, and P. M. Schlievert. 2000. Toxoids of streptococcal pyrogenic exotoxin A are protective in rabbit models of streptococcal toxic shock syndrome. Infect. Immun. 68:5011-5017.
39. Schlievert, P. M. 2009. Cytolysins, superantigens, and pneumonia due to community-associated methicillin-resistant Staphylococcus aureus. J. Infect. Dis. 200:676-678.
40. Schlievert, P. M. 1982. Enhancement of host susceptibility to lethal endotoxin shock by staphylococcal pyrogenic exotoxin type C. Infect. Immun. 36:123-128.
41. Schlievert, P. M., K. N. Shands, B. B. Dan, G. P. Schmid, and R. D. Nishimura. 1981. Identification and characterization of an exotoxin from Staphylococcus aureus associated with toxic-shock syndrome. J. Infect. Dis. 143:509-516.
42. Schlievert, P. M., K. L. Strandberg, Y. C. Lin, M. L. Peterson, and D. Y. Leung. 2010. Secreted virulence factor comparison between methicillin-resistant and methicillin-sensitive Staphylococcus aureus, and its relevance to atopic dermatitis. J. Allergy Clin. Immunol. 125:39-49.
43. Shands, K. N., G. P. Schmid, B. B. Dan, D. Blum, R. J. Guidotti, N. T. Hargrett, R. L. Anderson, D. L. Hill, C. V. Broome, J. D. Band, and D. W. Fraser. 1980. Toxic-shock syndrome in menstruating women: association with tampon use and Staphylococcus aureus and clinical features in 52 cases. N. Engl. J. Med. 303:1436-1442.
44. Shusta, E. V., M. C. Kieke, E. Parke, D. M. Kranz, and K. D. Wittrup. 1999. Yeast polypeptide fusion surface display levels predict thermal stability and soluble secretion efficiency. J. Mol. Biol. 292:949-956.
45. Stevens, D. L. 1995. Streptococcal toxic-shock syndrome: spectrum of disease, pathogenesis, and new concepts in treatment. Emerg. Infect. Dis. 1:69-78.
46. Stevens, D. L., M. H. Tanner, J. Winship, R. Swarts, K. M. Ries, P. M. Schlievert, and E. Kaplan. 1989. Severe group A streptococcal infections associated with a toxic shock-like syndrome and scarlet fever toxin A. N. Engl. J. Med. 321:1-7.
47. Sundberg, E. J. 2009. Molecular recognition of diverse ligands by T-cell receptors. Methods Mol. Biol. 524:347-359.
48. Sundberg, E. J., H. Li, A. S. Llera, J. K. McCormick, J. Tormo, P. M. Schlievert, K. Karjalainen, and R. A. Mariuzza. 2002. Structures of two streptococcal superantigens bound to TCR beta chains reveal diversity in the architecture of T cell signaling complexes. Structure (Camb.) 10:687-699.
49. Tilahun, M. E., G. Rajagopalan, N. Shah-Mahoney, R. G. Lawlor, A. Y. Tilahun, C. Xie, K. Natarajan, D. H. Margulies, D. I. Ratner, B. A. Osborne, and R. A. Goldsby. 2010. Potent neutralization of staphylococcal enterotoxin B by synergistic action of chimeric antibodies. Infect. Immun. 78:2801-2811.
50. Todd, J., M. Fishaut, F. Kapral, and T. Welch. 1978. Toxic-shock syndrome associated with phage-group-I staphylococci. Lancet ii:1116-1118. (Pubitemid 9060056)
51. Ulrich, R. G. 2008. Vaccine based on a ubiquitous cysteinyl protease and streptococcal pyrogenic exotoxin A protects against Streptococcus pyogenes sepsis and toxic shock. J. Immune Based Ther. Vaccines 6:8.
52. Ulrich, R. G., M. A. Olson, and S. Bavari. 1998. Development of engineered vaccines effective against structurally related bacterial superantigens. Vaccine 16:1857-1864.
53. Weeks, C. R., and J. J. Ferretti. 1986. Nucleotide sequence of the type A streptococcal exotoxin (erythrogenic toxin) gene from Streptococcus pyogenes bacteriophage T12. Infect. Immun. 52:144-150.